{
    "nct_id": "NCT05909397",
    "official_title": "A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ARV-471(PF-07850327) PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI-CANCER TREATMENT FOR ADVANCED DISEASE (VERITAC-3)",
    "inclusion_criteria": "* Adult participants with loco-regional recurrent or metastatic disease not amenable to curative treatment\n* Confirmed diagnosis of ER+/HER2- breast cancer\n* No prior systemic treatment for loco-regional recurrent or metastatic disease\n* Measurable disease evaluable per Response Evaluation Criterion in Solid Tumors (RECIST) v.1.1 or non-measurable bone-only disease\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Phase 3 only: Participants should be willing to provide blood and tumor tissue\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Disease recurrence while on, or within 12 months of completion of adjuvant endocrine therapy\n* Prior treatment with cyclin dependent kinase 4/6 inhibitors (CDK4/6i), fulvestrant, elacestrant and other investigational drugs including novel endocrine therapies, any selective estrogen receptor degraders (SERDs), covalent antagonists (SERCAs) and complete ER antagonists (CERANs).\n* Inadequate liver, kidney and bone marrow function\n* Impaired cardiovascular function or clinically significant cardiovascular diseases\n* Refractory nausea and vomiting, inability to swallow capsules and tablets whole, chronic gastrointestinal diseases, significant gastric (total or partial) or bowel resection that would preclude adequate absorption of study interventions.\n* Current use or anticipated need for food, herbal supplements or drugs that are known strong CYP3A4 inhibitors or inducers.",
    "miscellaneous_criteria": ""
}